| CNP-201 in Subjects With Peanut Allergy (NCT05250856) | COUR Pharmaceutical Development Company, Inc. | 2022-03-14 |
| Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy (NCT04872218) | Philippe Bégin | 2022-03-01 |
| Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety (NCT06256146) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2022-03-01 |
| Induction of Sustained Unresponsiveness to Peanuts Using High- and Low-dose Peanut Oral Immunotherapy (NCT05163574) | Medical University of Warsaw | 2022-02-05 |
| Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy (NCT05138757) | University of Chicago | 2021-11-30 |
| A Randomized, Controlled Trial of Probiotic and Peanut Oral Immunotherapy (PPOIT) in Inducing Tolerance in Hong Kong Children With Peanut Allergy Compared With Oral Immunotherapy (OIT) Alone and With Placebo (NCT05165329) | Chinese University of Hong Kong | 2021-11-11 |
| STEP-IT-UP - Peanut Allergy Study for Infants (NCT04761835) | Johns Hopkins University | 2021-11-01 |
| Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy (NCT04950504) | COUR Pharmaceutical Development Company, Inc. | 2021-06-02 |
| OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut (NCT04603300) | Intrommune Therapeutics | 2021-05-15 |
| High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety (NCT04415593) | Medical University of Warsaw | 2020-09-01 |
| Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT (NCT04511494) | Karolinska Institutet | 2020-09-01 |
| Food Oral Immunotherapy for Peanut Allergy (NCT04222491) | Massachusetts General Hospital | 2020-06-25 |
| Oral Immunotherapy for Peanut Allergic Patients (NCT04163562) | InnoUp Farma S.L. | 2020-03-11 |
| Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE) (NCT03679676) | Stanford University | 2020-02-05 |
| Validation of the HYPONUT Product (NCT03849079) | University Hospital, Montpellier | 2019-09-24 |
| Allergology: Information, Data and Knowledge Organization (NCT04887441) | University Hospital, Montpellier | 2019-09-01 |
| Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy (NCT03907397) | Scott Sicherer | 2019-08-05 |
| Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (NCT03881696) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-07-22 |
| VE416 for Treatment of Food Allergy (NCT03936998) | Massachusetts General Hospital | 2019-06-28 |
| Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy (NCT04974970) | University Hospital, Geneva | 2019-04-01 |
| A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine (NCT03755713) | Astellas Pharma Global Development, Inc. | 2019-03-12 |
| Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy (NCT03793608) | Regeneron Pharmaceuticals | 2019-03-12 |
| Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (NCT03736447) | Aimmune Therapeutics, Inc. | 2018-12-27 |
| Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children (NCT03859700) | DBV Technologies | 2018-12-06 |
| Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents (NCT03703791) | Aimmune Therapeutics, Inc. | 2018-10-24 |
| The Grown Up Peanut Immunotherapy Study (NCT03648320) | Guy's and St Thomas' NHS Foundation Trust | 2018-10-15 |
| Reactive Doses and Times During Oral Food Challenge to Peanut (NCT03852342) | University Hospital, Montpellier | 2018-10-10 |
| Oral Low Doses Tolerance INduction Study for Peanuts (NCT04881773) | University Hospital, Montpellier | 2018-09-01 |
| Follow up of LEAP Participants and Their Families (NCT03546413) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-05 |
| Study to Assess Tolerance of Traces in Peanut/Tree Nut Allergic Children. (NCT03680066) | University Hospital, Geneva | 2018-04-01 |
| Peanut and Tree Nut Desensitization (NCT03532360) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2018-02-19 |
| Salvage Peanut Oral Immunotherapy Study (NCT03251508) | University of North Carolina, Chapel Hill | 2018-01-03 |
| A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects (NCT03352726) | DBV Technologies | 2017-11-24 |
| Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) (NCT03292484) | Aimmune Therapeutics, Inc. | 2017-11-02 |
| AR101 Real-World Open-Label Extension Study (NCT03337542) | Aimmune Therapeutics, Inc. | 2017-10-18 |
| Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age (NCT03211247) | DBV Technologies | 2017-07-31 |
| ARTEMIS Peanut Allergy In Children (NCT03201003) | Aimmune Therapeutics, Inc. | 2017-06-12 |
| Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) (NCT03126227) | Aimmune Therapeutics, Inc. | 2017-05-08 |
| Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic Patients (NCT02960074) | Rima Rachid | 2017-03-03 |
| Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy (NCT02920021) | AnaptysBio, Inc. | 2017-01-26 |
| Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children (NCT03013517) | DBV Technologies | 2017-01-23 |
| Allergy Experience Study (NCT03513965) | Stanford University | 2017-01-05 |
| PALISADE Follow-on Study (ARC004) (NCT02993107) | Aimmune Therapeutics, Inc. | 2016-12-29 |
| A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine (NCT02851277) | Astellas Pharma Global Development, Inc. | 2016-12-13 |
| HAL-MPE1 Safety and Tolerability Study (NCT02991885) | HAL Allergy | 2016-12-01 |
| Early Peanut Introduction: Translation to Clinical Practice (NCT03019328) | Johns Hopkins University | 2016-12-01 |
| Safety Study of Viaskin Peanut to Treat Peanut Allergy (NCT02916446) | DBV Technologies | 2016-10-01 |
| Identification of Anaphylactogenic Antibodies in Peanut Allergy (NCT02821286) | University of Zurich | 2016-06-01 |
| Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) (NCT02635776) | Aimmune Therapeutics, Inc. | 2015-12-22 |
| High Threshold Peanut Challenge Study (NCT02698033) | Massachusetts General Hospital | 2015-12-09 |
| Visual Recognition of Allergens by Allergic Patients and/or Their Parents (NCT02966938) | Lille Catholic University | 2015-12-01 |
| Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy (NCT02636699) | DBV Technologies | 2015-12-01 |
| Clinical and Biological Efficacy of Peanut Oral Immunotherapy (NCT02979600) | Lille Catholic University | 2015-09-01 |
| Reduction of Peanut Reactivity and Immune Modulation With Anti-IgE Therapy (NCT02194530) | Weill Medical College of Cornell University | 2015-03-30 |
| Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study (NCT02198664) | Aimmune Therapeutics, Inc. | 2014-08-27 |
| HAL-MPE1 First-in-human (NCT02163018) | HAL Allergy | 2014-06-01 |
| The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery (NCT02103270) | Stanford University | 2014-04-01 |
| Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT (NCT01987817) | Aimmune Therapeutics, Inc. | 2014-02-06 |
| Walnut Oral Immunotherapy for Tree Nut Allergy (NCT01918657) | Jonathan Spergel | 2014-02-01 |
| Evaluating Peanut Immunotherapy Dissolving Film in Healthy Subjects (NCT03070561) | Johns Hopkins University | 2014-01-14 |
| Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy (NCT02402231) | Caroline Nilsson | 2013-10-01 |
| Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children (NCT01955109) | DBV Technologies | 2013-09-01 |
| The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy (NCT01950533) | National Jewish Health | 2013-09-01 |
| Tolerance Following Peanut Oral Immunotherapy (NCT01750879) | Massachusetts General Hospital | 2013-08-01 |
| Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers (NCT02046083) | University Hospital, Clermont-Ferrand | 2013-07-18 |
| Canadian Peanut Thresholds Study (NCT01812798) | McMaster University | 2013-05-01 |
| Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial (NCT01781637) | Boston Children's Hospital | 2013-01-01 |
| The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy (NCT01897077) | Johns Hopkins University | 2012-11-01 |
| Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy (NCT01675882) | DBV Technologies | 2012-08-01 |
| Peanut Allergy Oral Immunotherapy Desensitization (NCT01601522) | Hamilton Health Sciences Corporation | 2012-02-01 |
| Evaluation of Allergenicity of Hypoallergenic Peanut Product in Peanut Allergic Subjects (NCT01489514) | University of North Carolina, Chapel Hill | 2011-12-01 |
| Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance (NCT01373242) | University of North Carolina, Chapel Hill | 2011-06-01 |
| Oral Peanut Immunotherapy (NCT01324401) | Massachusetts General Hospital | 2011-03-01 |
| Xolair Enhances Oral Desensitization in Peanut Allergic Patients (NCT01290913) | Lynda Schneider | 2011-02-01 |
| Understanding How the Immune System Responds to Viruses in Peanut Allergic Children Undergoing Peanut Oral Immunotherapy (NCT01074840) | University of Texas Southwestern Medical Center | 2010-02-01 |
| Omalizumab in the Treatment of Peanut Allergy (NCT00949078) | Johns Hopkins University | 2009-07-01 |
| Study of Tolerance to Oral Peanut (NCT01259804) | Cambridge University Hospitals NHS Foundation Trust | 2008-01-01 |
| Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children (NCT05424731) | DBV Technologies | |
| Viaskin® Peanut (DBV712) Expanded Access Protocol (NCT04371627) | DBV Technologies | |